search
Back to results

Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy

Primary Purpose

Diabetic Nephropathy Type 2

Status
Unknown status
Phase
Phase 2
Locations
Mexico
Study Type
Interventional
Intervention
green tea extract
Placebo
Sponsored by
Centro Universitario de Ciencias de la Salud, Mexico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Nephropathy Type 2 focused on measuring Green tea extract, Kidney damage, type 2 diabetes mellitus

Eligibility Criteria

40 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • People of both sexes
  • Age from 40 to 65 years
  • Signature of consent under information
  • Diagnosis of type 2 diabetes mellituswith stable pharmacological treatment
  • Glomerular filtration rate between 89 - 45 ml / min / 1.73 m2
  • Albumin / creatinine ratio ≤ 30 - 300 mg / min
  • HbA1c levels 7 - 12%
  • Body mass index - 34.9

Exclusion Criteria:

  • Glomerular filtration rat lower than 44 ml / min / 1.73 m2
  • Albumin / creatinine ratio ≥ 300
  • Other causes of kidney disease
  • Other types of Diabetes
  • Liver, thyroid or heart diseases
  • Intolerance related to green tea or placebo components
  • Use of antioxidant supplements
  • Active alcoholism
  • Patients with pregnancy or without a safe contraceptive method
  • Patients in breastfeeding period

Sites / Locations

  • Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of GuadalajaraRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Green tea extract

Placebo

Arm Description

In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines

In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines

Outcomes

Primary Outcome Measures

Soluble RAGE concentration
Before and after the intervention using the serum extracted from the patient using sandwich ELISA.

Secondary Outcome Measures

Glomerular filtration rate
Before and after the intervention, it will be evaluated by means of a determination of serum creatinine, which will be analyzed with the spectrophotometry method and from its result the glomerular filtration rate is calculated.
Albumin/creatinine ratio
Before and after intervention by spectrophotometry
Fasting plasma glucose
Before and after intervention spectrophotometry
Glycated Hemoglobin concentration
It will be analyzed by liquid chromatography
Systolic and diastolic arterial pressure
Before and after intervention using a digital baumanometer
Alanine aminotransferase
Before and after intervention by spectrophotometry
Aspartate aminotransferase
Before and after intervention by spectrophotometry

Full Information

First Posted
August 6, 2018
Last Updated
February 19, 2019
Sponsor
Centro Universitario de Ciencias de la Salud, Mexico
search

1. Study Identification

Unique Protocol Identification Number
NCT03622762
Brief Title
Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy
Official Title
Effect of the Administration of Green Tea Extract on Soluble RAGE and Kidney Disease in Patients With Diabetes Mellitus Type 2
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 15, 2018 (Actual)
Primary Completion Date
March 15, 2019 (Anticipated)
Study Completion Date
June 20, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centro Universitario de Ciencias de la Salud, Mexico

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Diabetic nephropathy is one of the most feared complications of Diabetes Mellitus type 2, characterized mainly by the decrease in the glomerular filtration rate and an increase in protein secretion by the kidney, that results in proteinuria. This has led to the development of intensive treatment regimens for patients with diabetes and preventive measures since once the complications have already presented the improvement of glycemic control alone may not be enough, to prevent the progression of pathological processes. Currently, interventions to delay the progression of kidney damage, include changes in lifestyle, nutritional advice and regular exercise, achieve optimal levels in glycemic control and use of pharmacological therapies with nephroprotector, angiotensin II receptor blocker (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs). The most important biochemical mechanism proposed for this progression is the excessive binding of glucose to proteins, better described as the final products of advanced glycosylation (AGEs); the interaction of AGEs with its receptor (RAGE), participates in the metabolic and biochemical pathways in intracellular signaling, either by favoring or aggravating cell nephron damage. Recently, numerous RAGE isoforms have been described as: soluble RAGE, which are devoid of cytoplasmic domains, which bind to ligands that include AGEs and can antagonize intracellular signaling. Therefore, the need to seek for alternative therapies like nutraceuticals is arising, mainly due to its low toxicity and lower cost. Such is the case of green tea extract, which due to its chemical composition, especially of flavonoids that generate antioxidant and anti-inflammatory effects, In vivo and in clinical trials have shown that it could impact the progression of the diabetic neuropathy , through the modulation of the biological process, including molecular and biochemical pathways such as release of soluble RAGE.
Detailed Description
The objective of the study is to evaluate the effect of the administration of green tea extract on soluble RAGE and renal damage in patients with Type 2 Diabetes Mellitus, by means of a clinical trial, double blind, with randomization and placebo control group. In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage, 2 - 3a grade according to classification of the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines and HbA1c levels 9 - 12% who sign the letter of consent under information, from 35 to 65 years of age, residents of the metropolitan area of Guadalajara. All patients who meet the selection criteria and who sign their informed consent will be given the clinical history, as well as anthropometric and laboratory determinations. Once these values are known, the intervention will proceed with the research product, extract of green tea 400 mg twice a day or placebo 400 mg twice a day, this will be according to the technique of masking by the closed envelope technique for 12 weeks. Patients will be evaluated at 30, 60 and 90 days of intervention, for attachment assessment, tolerability of treatment, side effects and laboratory safety determinations. At the end of the 12 weeks of the intervention, the anthropometric and laboratory determinations will be made again as well as the determination of soluble RAGE by means of Elisa sandwich type, in serum obtained at the beginning and at 12 weeks of intervention. The database will be developed in the statistical program Statistical software (SPSS) version 21.0. The qualitative variables will be expressed in frequencies and percentages, while the quantitative variables will be expressed in means and standard deviations, the normality test will be carried out through the Kolmogorov-Smirnov test and, according to the result, it will be decided for the analysis intra group perform paired t or Wilcoxon method and for intergroup t student or Mann-Whitney U. A value of p ≤0.05 will be considered statistically significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Nephropathy Type 2
Keywords
Green tea extract, Kidney damage, type 2 diabetes mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Green tea extract
Arm Type
Experimental
Arm Description
In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
Intervention Type
Drug
Intervention Name(s)
green tea extract
Other Intervention Name(s)
Sunphenon
Intervention Description
Capsules of green tea extract, 400 mg twice a day, fasting
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Calcined magnesium
Intervention Description
Placebo capsules, 400 mg twice daily fasting
Primary Outcome Measure Information:
Title
Soluble RAGE concentration
Description
Before and after the intervention using the serum extracted from the patient using sandwich ELISA.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Glomerular filtration rate
Description
Before and after the intervention, it will be evaluated by means of a determination of serum creatinine, which will be analyzed with the spectrophotometry method and from its result the glomerular filtration rate is calculated.
Time Frame
90 days
Title
Albumin/creatinine ratio
Description
Before and after intervention by spectrophotometry
Time Frame
90 days
Title
Fasting plasma glucose
Description
Before and after intervention spectrophotometry
Time Frame
90 days
Title
Glycated Hemoglobin concentration
Description
It will be analyzed by liquid chromatography
Time Frame
90 days
Title
Systolic and diastolic arterial pressure
Description
Before and after intervention using a digital baumanometer
Time Frame
90 days
Title
Alanine aminotransferase
Description
Before and after intervention by spectrophotometry
Time Frame
90 days
Title
Aspartate aminotransferase
Description
Before and after intervention by spectrophotometry
Time Frame
90 days
Other Pre-specified Outcome Measures:
Title
Total cholesterol
Description
Before and after intervention by spectrophotometry
Time Frame
90 days
Title
triglycerides
Description
Before and after intervention by spectrophotometry
Time Frame
90 days
Title
High-density lipoprotein cholesterol
Description
Before and after intervention by spectrophotometry
Time Frame
90 days
Title
Low-density lipoprotein cholesterol
Description
Before and after intervention by friedewall formula
Time Frame
90 days
Title
Weight and visceral fat %
Description
Before and after intervention using a vascula of impedance
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: People of both sexes Age from 40 to 65 years Signature of consent under information Diagnosis of type 2 diabetes mellituswith stable pharmacological treatment Glomerular filtration rate between 89 - 45 ml / min / 1.73 m2 Albumin / creatinine ratio ≤ 30 - 300 mg / min HbA1c levels 7 - 12% Body mass index - 34.9 Exclusion Criteria: Glomerular filtration rat lower than 44 ml / min / 1.73 m2 Albumin / creatinine ratio ≥ 300 Other causes of kidney disease Other types of Diabetes Liver, thyroid or heart diseases Intolerance related to green tea or placebo components Use of antioxidant supplements Active alcoholism Patients with pregnancy or without a safe contraceptive method Patients in breastfeeding period
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fernando Grover Páez, PhD
Phone
(33) 10585200
Ext
34215
Email
fgroverp@hotmail.com
Facility Information:
Facility Name
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44340
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fernando Grover Paez, PhD
Phone
(33) 10585200
Ext
34215
Email
fgroverp@hotmail.com
First Name & Middle Initial & Last Name & Degree
Fernando Grover Paez, PhD
Phone
(33) 10585200
Ext
34215
Email
marycruz_bp91@hotmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34788550
Citation
Barocio-Pantoja M, Quezada-Fernandez P, Cardona-Muller D, Jimenez-Cazarez MB, Larios-Cardenas M, Gonzalez-Radillo OI, Garcia-Sanchez A, Carmona-Huerta J, Chavez-Guzman AN, Diaz-Preciado PA, Balleza-Alejandri R, Pascoe-Gonzalez S, Grover-Paez F. Green Tea Extract Increases Soluble RAGE and Improves Renal Function in Patients with Diabetic Nephropathy. J Med Food. 2021 Dec;24(12):1264-1270. doi: 10.1089/jmf.2020.0212. Epub 2021 Nov 17.
Results Reference
derived

Learn more about this trial

Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy

We'll reach out to this number within 24 hrs